A Primary Hepatic Lymphoma in a Patient with Crohn's Disease Receiving Thiopurine and Anti-TNF Therapy: a Case Report

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2023 Sep 27

PMID 37753362

Authors

Salma Merhaben

Shema Ayadi

Monia Tangour

Nadia Boujelbene

Rayfa Ghariani

Leila Mouelhi

Fathi Merhaben

Affiliations

Soon will be listed here.

Abstract

Primary hepatic lymphoma is a rare variant of non-Hodgkin's lymphoma with an incidence of 0.016% of all non-Hodgkin lymphomas. The most common histologic subtype is large diffuse B-cell lymphoma. Pathogenesis is not clearly established and undergoing immunosuppressive therapy has been proposed as a risk factor for primary hepatic lymphoma. We report an intriguing case study, featuring a 23-year-old male patient with Crohn's Disease who had been receiving a combination therapy of thiopurine and anti-TNF for 6 years and was diagnosed with primary hepatic diffuse large B-cell lymphoma.

Citing Articles

A Case Report of Follicular Lymphoma in a Crohn's Disease Patient Treated With Azathioprine.

Kottavadakkeel N, Farzina R, Rajaram A, Mannath S, Sunil A Cureus. 2023; 15(12):e50839.

PMID: 38125685 PMC: 10732096. DOI: 10.7759/cureus.50839.

References

Qiu M, Fang X, Huang Z, Li Q, Wang M, Jiang X . Prognosis of primary hepatic lymphoma: A US population-based analysis. Transl Oncol. 2020; 14(1):100931. PMC: 7672323. DOI: 10.1016/j.tranon.2020.100931. View

Forrest M, Skibola C, Lightfoot T, Bracci P, Willett E, Smith M . Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol. 2006; 134(2):180-3. DOI: 10.1111/j.1365-2141.2006.06141.x. View

Rezk S, Weiss L . Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007; 38(9):1293-304. DOI: 10.1016/j.humpath.2007.05.020. View

Nocturne G, Boudaoud S, Ly B, Pascaud J, Paoletti A, Mariette X . Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J Autoimmun. 2017; 80:56-64. DOI: 10.1016/j.jaut.2017.02.001. View

Beaugerie L, Brousse N, Bouvier A, Colombel J, Lemann M, Cosnes J . Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701):1617-25. DOI: 10.1016/S0140-6736(09)61302-7. View

Williams C, Peyrin-Biroulet L, Ford A . Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39(5):447-58. DOI: 10.1111/apt.12624. View

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S . Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311(23):2406-13. DOI: 10.1001/jama.2014.5613. View

Sokol H, Beaugerie L, Maynadie M, Laharie D, Dupas J, Flourie B . Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18(11):2063-71. DOI: 10.1002/ibd.22889. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

10.

Turner D, Ricciuto A, Lewis A, DAmico F, Dhaliwal J, Griffiths A . STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2020; 160(5):1570-1583. DOI: 10.1053/j.gastro.2020.12.031. View

11.

Severyns T, Kirchgesner J, Lambert J, Thieblemont C, Amiot A, Abitbol V . Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. J Crohns Colitis. 2020; 14(9):1222-1230. DOI: 10.1093/ecco-jcc/jjaa048. View

12.

Haider F, Smith R, Khan S . Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report. J Med Case Rep. 2008; 2:279. PMC: 2542397. DOI: 10.1186/1752-1947-2-279. View

13.

Noronha V, Shafi N, Obando J, Kummar S . Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol. 2005; 53(3):199-207. DOI: 10.1016/j.critrevonc.2004.10.010. View

14.

Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N . Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. J Crohns Colitis. 2016; 10(11):1259-1266. DOI: 10.1093/ecco-jcc/jjw152. View

15.

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F . Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017; 318(17):1679-1686. PMC: 5818785. DOI: 10.1001/jama.2017.16071. View

16.

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C . European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11):945-65. DOI: 10.1093/ecco-jcc/jjv141. View

17.

Herrinton L, Liu L, Weng X, Lewis J, Hutfless S, Allison J . Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011; 106(12):2146-53. DOI: 10.1038/ajg.2011.283. View

18.

Cesaretti M, Loustau M, Robba C, Senescende L, Zarzavadjian Le Bian A . Reappraisal of primary hepatic lymphoma: Is surgical resection underestimated?. Crit Rev Oncol Hematol. 2018; 123:1-6. DOI: 10.1016/j.critrevonc.2018.01.004. View